Ezetimibe final guidance [Regulatives / Guidelines]

posted by Helmut Homepage – Vienna, Austria, 2019-09-28 12:11 (966 d 18:59 ago) – Posting: # 20650
Views: 3,525

Hi Mutasim & all,

yesterday at BioBridges Paola Coppola (MHRA, PKWP observer) presented the state of affairs. The ezetimibe guidance is finalized and will be published soon. No changes to the draft. You are right and I was wrong. One should indeed measure both ezetimibe and its glucuronide. BE should be based on their sum* only.

I still think that’s stupid. Both methods have errors (inaccurate, imprecise). If you evaluate the sum of concentrations, errors will sum up as well. Given, the concentrations of the glucuronide are two orders of magnitude higher than the parent’s and hence, the impact of the latter is negligible.
At the BioInternational 1994 in Munich there was a nice distinction between “Need to know” and “Nice to know”. I don’t like the idea that something which is only nice to know (i.e., not used in the assessment for BE) is mandatory in a guidance. :thumb down:



Dif-tor heh smusma 🖖 [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
22,091 posts in 4,630 threads, 1,566 registered users;
online 8 (0 registered, 8 guests [including 7 identified bots]).
Forum time: Sunday 07:11 CEST (Europe/Vienna)

Competence, like truth, beauty and contact lenses,
is in the eye of the beholder.    Laurence J. Peter

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5